ライフサイエンスコーパス: multifocality

1 in subsequent enlargement or progression to multifocality.

2 d cancer owing to an increased prevalence of multifocality.

3 rge tumor size, extrathyroidal extension and multifocality.

4 ese tools to advance the field of refractive multifocality.

5 h contiguous enlargement than progression to multifocality.

6 /200 (15% vs 28%), bilaterality (4% vs 20%), multifocality (5% vs 15%), postequatorial tumor location

7 ary thyroid carcinoma (6 [55%] vs 13 [18%]), multifocality (9 [82%] vs 28 [41%]), microscopic extrath

8 2-4% of "sporadic" multifocality and 5-8% of hereditary syndromes are accep

9 ns can be adjusted to create both refractive multifocality and diffractive bifocality.

10 tion, size, mass effect/oedema, enhancement, multifocality and fulfilment of Barkhof criteria.

11 The extensive multifocality and genetic heterogeneity of PanINs raises

12 nts and are complicated by the potential for multifocality and involvement of multiple target tissues

13 odel was used to evaluate the association of multifocality and OS and identify additional prognostic

14 asingly, the roles of differential genomics, multifocality and spatial distribution in tumorigenesis

15 poradic BCs, including younger age of onset, multifocality, and an increased risk of second primary B

16 size, histologic subtype, malignancy grade, multifocality, and completeness of resection were signif

17 pe, lymphovascular invasion, tumor location, multifocality, and estrogen and progesterone receptors w

18 lomatous and nodular appearance, microscopic multifocality, and positive margins on biopsy.

19 ry surgery without subsequent RAI, and tumor multifocality are factors that are strongly prognostic f

20 ence does not predict central involvement or multifocality at GA incidence but is associated with fas

21 d to be a benign proliferation caused by its multifocality at initial presentation, lack of aneuploid

22 gnificant association between higher PGS and multifocality (beta [SE], 0.40 [0.23]; P = .045) and cer

23 Although margin was predictive of DSS, multifocality calls into question the reliability of neg

24 table lenses plus injectable technology, and multifocality can produce precise refractive correction

25 Multifocality did not affect lymph node metastasis in tu

26 ive progression in the remnant gland include multifocality, diffuse main duct dilation, and the prese

27 proportional hazards model demonstrated that multifocality, extrahepatic extension, grade, node posit

28 orts: baseline lesion size, lesion location, multifocality, FAF patterns, and fellow eye status.

29 a (HCC) is characterized by a propensity for multifocality, growth by local spread, and dysregulation

30 mline testing based on a combination of age, multifocality, histologic findings, and family history.

31 After risk-adjustment, multifocality (HR 4.53, 95%CI 1.34-15.26; P = 0.02) and

32 (HR, 2.90 [95% CI, 1.17-7.20]; P = .02), and multifocality (HR, 2.92 [95% CI, 1.70-5.00]; P < .001) w

33 PET/CT were concordantly positive for tumor multifocality in 5 patients, discordantly positive in 2

34 MR imaging demonstrated multifocality in all patients.

35 cal features, and prognostic significance of multifocality in RPS is unknown.

36 1 invasive feature-extrathyroidal extension, multifocality, lymphovascular invasion, nodal or distant

37 cally characterized by right-sided location, multifocality, mucinous histology, and lymphocytic infil

38 hape, margin, lymph node involvement, grade, multifocality, multicentricity, bilaterality, and enhanc

39 ata system (BI-RADS) category, bilaterality, multifocality, multicentricity, margin, shape, and T2W i

40 f other MRI findings including bilaterality, multifocality, multicentricity, shape, and T2W image int

41 The diagnosis of multifocality/multicentricity invasive index cancer was

42 On univariate analysis, multifocality/multicentricity of the index cancer was th

43 ing comorbidities, extrathyroidal extension, multifocality, nodal and distant metastases, and radioac

44 f the whole-body bone scan in diagnosing the multifocality of chronic recurrent multifocal osteomyeli

45 the phenotype in the mice closely resembled multifocality of clinical disease.

46 ch as number of pathologists confirming LGD, multifocality of LGD, and persistence of LGD over time.

47 In multivariate analysis, multifocality on final pathology was associated with dis

48 If there is no evidence of unilateral multifocality or if there are fewer than 4 positive lymp

49 esection because of tumor size, location, or multifocality or inadequate functional hepatic reserve.

50 atient survival was negatively influenced by multifocality (p = 0.0021) and an age older than 60 year

51 ), initial treatment (P = 0.0001), and tumor multifocality (P = 0.011).

52 elihood of central involvement (P = 0.29) or multifocality (P = 0.16) at incidence.

53 liver transplantation if local invasion and multifocality preclude resection.

54 age, tumor size, grade, histologic subtype, multifocality, quality of surgery, and radiation therapy

55 After multivariate analysis, multifocality remained an independent predictor of worse

56 ble disease (because of poor lung reserve or multifocality) underwent nodule CT densitometry and CT-g

57 In patients with T1b tumors, unilateral multifocality was also associated with bilateral disease

58 Of those with T1a, unilateral multifocality was associated with bilateral disease (odd

59 Multifocality was characterized with both methods in 31

60 Intestinal tumor multifocality was confirmed by histology in 8 patients.

61 Multifocality was determined when alternate patterns of

62 rtional hazards regression of progression to multifocality were analyzed by ARMS2 genotype.

63 All invasive features, except multifocality, were independently associated with worse

64 Multifocality, young age, familiar history, syndromic da